featured
Ide-Cel vs Standard Regimens for Triple Class–Exposed Relapsed and Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses
Blood 2024 Aug 28;[EPub Ahead of Print], S Ailawadhi, B Arnulf, KK Patel, M Cavo, AK Nooka, S Manier, NS Callander, LJ Costa, R Vij, NJ Bahlis, P Moreau, SR Solomon, IW Abrahamsen, RC Baz, A Broijl, C Chen, S Jagannath, N Raje, C Scheid, M Delforge, R Benjamin, T Pabst, S Iida, JG Berdeja, SA Giralt, A Truppel-Hartmann, Y Chen, X Zhong, F Wu, J Piasecki, L Eliason, DS Dhanda, J Felten, A Caia, M Cook, M Popa-Mckiver, P Rodriguez-OteroFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.